A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

NCT06528301 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma, B-Cell
Lymphoma, Non-Hodgkin (NHL)
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Chronic Lymphocytic Leukemia (CLL)

Interventions

GENETIC: UB-VV111
DRUG: rapamycin

Sponsor

Umoja Biopharma